Revvity launches Signals BioDesign™
The cloud-native solution streamlines biologics research workflows and enhances R&D collaboration.
See the latest news and media coverage for Revvity. We track all announcements, press releases, and industry mentions in real time, all in one place.
Health science technologies and services company
revvity.comLast updated
In short: Revvity reported strong 2026 Q1 and 2025 Q4 financial results, surpassing analyst estimates while announcing the divestiture of its China business.
The cloud-native solution streamlines biologics research workflows and enhances R&D collaboration.
Reports $711M revenue, 7% growth, adjusted EPS $1.06. Intends to divest China Immunodiagnostics business. Updates 2026 guidance to $2.81-2.84B revenue.
Presentations include BofA Health Care (May 13) and Goldman Sachs Global Healthcare (June 9). Live webcasts and 30-day replays will be available.
It streamlines molecular cloning workflows for biotech and pharma R&D, enabling high-throughput construct design up to 1,000 with real-time collaboration and Signals One integration.
On October 03, 2023, Wolfe Research has officially assumed coverage of Revvity (RVTY) with a rating...
Revvity remained in focus following quarterly results as laboratory technology, scientific research, diagnostic solutions, ...
Revvity (RVTY) stock still attractive to investors? Coverage includes breakout stock potential, trading momentum trends, earnings outlook with expert market analysis updated daily. Revvity Inc...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
Track Revvity and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Revvity and other trending companies.